CareFusion 213's BD ChloraPrep Clear Recalled Nationwide Over Sterility Concerns
CareFusion 213, LLC, a Becton, Dickinson and Co. subsidiary, has initiated a Class II recall for 385,200 applicators of BD ChloraPrep Clear due to potential sterility breaches from open packaging seals. This nationwide U.S. recall, affecting critical preoperative skin preparation, mandates immediate action from procurement and regulatory teams to mitigate patient safety risks and ensure supply chain integrity.
FDA Class II Recall: CareFusion 213's BD ChloraPrep Clear Faces Sterility Concerns
CareFusion 213, LLC, a subsidiary of Becton, Dickinson and Co., has initiated a voluntary Class II recall, designated D-0441-2025, for its BD ChloraPrep Clear, 2% chlorhexidine gluconate (CHG) and 70% isopropyl alcohol (IPA) Patient Preoperative Skin Preparation. The recall, commenced on May 15, 2025, addresses a critical "Lack of Assurance of Sterility" stemming from the potential for an open seal on the applicator’s packaging. This defect compromises the sterile integrity of a product designed for critical infection prevention prior to medical procedures. A total of 385,200 applicators are impacted, specifically from Lot #s 3354127 and 3350974, both bearing an expiration date of December 31, 2026. For procurement directors and supply chain VPs, this means an immediate need to identify and quarantine these specific lots within their inventory. Failure to do so exposes healthcare facilities to significant patient safety risks, including potential surgical site infections, and increases liability. Regulatory affairs heads must ensure rapid compliance with recall instructions to mitigate adverse events and maintain regulatory standing.
Operational Impact from El Paso Facility on Sterile Product Supply
The affected BD ChloraPrep Clear products originate from CareFusion 213, LLC’s manufacturing facility in El Paso, TX, United States. As a key subsidiary of Becton, Dickinson and Co., CareFusion 213 plays a vital role in the supply of essential medical consumables. BD ChloraPrep Clear (NDA020832, NDC 54365-400-31) is a widely utilized sterile solution, crucial for reducing the risk of infection in various surgical and invasive medical procedures. The identified packaging integrity issue points to a potential lapse in quality control or manufacturing processes at the El Paso site, directly impacting the reliability of a foundational product in infection prevention. For business development executives, this event highlights the inherent risks associated with single-source reliance, even from established manufacturers like BD. Regulatory affairs teams must scrutinize their supplier qualification processes, particularly for sterile products, to ensure that manufacturing sites consistently meet stringent quality and sterility assurance standards, thereby safeguarding patient outcomes and brand reputation.
Supply Chain Disruption and Nationwide Market Exposure
The recall of BD ChloraPrep Clear has a nationwide distribution pattern within the U.S., indicating a broad impact across the healthcare sector. The substantial quantity of 385,200 applicators involved signifies a significant disruption to the supply chain for patient preoperative skin preparations. This product, containing chlorhexidine gluconate and isopropyl alcohol, is a staple in hospitals, surgical centers, and clinics for its efficacy in infection control. Procurement directors must immediately assess their current inventory levels of Catalog Number 930480 and other similar products to identify potential shortages. Supply chain VPs need to activate contingency plans, explore alternative sourcing for CHG/IPA solutions, and manage communication with downstream partners to ensure continuity of care. The recall’s Class II classification, while not the most severe, still implies a reasonable probability of temporary or medically reversible adverse health consequences, underscoring the urgency for robust supply chain resilience and proactive risk mitigation strategies.
Broader Regulatory Landscape: Sterility Assurance Under Scrutiny
This CareFusion 213 recall is not an isolated incident but rather indicative of a broader regulatory trend emphasizing rigorous sterility assurance across the pharmaceutical and medical device industries. The FDA consistently prioritizes robust manufacturing controls and packaging integrity, especially for sterile products like patient preoperative skin preparations. A parallel event, the Class II recall of Essential Wellness Pharma’s Progesterone Injection in June 2026 due to similar sterility assurance failures, underscores this heightened scrutiny. For regulatory affairs heads, this signals an imperative to re-evaluate internal quality management systems, risk assessments, and supplier audit programs. The FDA’s focus on preventing microbial contamination means that any lapse in aseptic processing or packaging integrity can lead to significant regulatory action and market disruption. Business development executives should recognize that investment in advanced manufacturing technologies and stringent quality control measures is no longer just a competitive advantage but a fundamental requirement for market access and sustained operational viability.
Navigating Remediation and Future Compliance Expectations
The recall of BD ChloraPrep Clear is currently designated as “Ongoing” and was “Voluntary: Firm initiated,” indicating that CareFusion 213, LLC is actively engaged in managing the event. While the firm initiated the recall, the FDA maintains oversight, particularly for Class II classifications. CareFusion 213, LLC will be expected to conduct a thorough root cause analysis to determine why the applicator seals were compromised and implement comprehensive corrective and preventive actions (CAPA) at its El Paso, TX facility. This will likely involve re-evaluating packaging processes, material specifications, and quality control checkpoints. For procurement directors, this ongoing status means potential for continued supply chain volatility from this specific product line until the issue is fully resolved and validated by the manufacturer and potentially the FDA. Regulatory affairs teams must prepare for potential increased scrutiny during future FDA inspections, focusing on the effectiveness of the implemented CAPA. Business development executives should consider diversifying their sourcing strategies for critical sterile products to mitigate future risks stemming from similar manufacturing or packaging integrity challenges within the industry.